Calix, Inc.
Historical Financial Statements
GAAP and Non-GAAP Condensed Consolidated Statements of Income (Loss) 2025

(\$ in thousands)	GAAP	Non-GAAP		GAAP	Non-GAAP		GAAP	Non-GAAP
	Qtr Ending	Qtr Ending	П	Qtr Ending	Qtr Ending		Ytd Ending	Ytd Ending
	3/29/2025	3/29/2025	11	6/28/2025	6/28/2025		6/28/2025	6/28/2025
						Ш.		
Revenue	\$ 220,242			\$ 241,882		\$	•	
Cost of revenue (1)(5)	97,534	96,456	▍┞	105,587	104,595	L	203,121	201,051
Gross profit	122,708	123,786		136,295	137,287		259,003	261,073
Gross margin %	55.7%	56.2%		56.3%	56.8%		56.0%	56.5%
Sales and marketing (2)	58,059	51,590		63,653	52,606		121,712	104,196
Research and development (3)	43,980	38,899		45,787	39,897		89,767	78,796
General and administrative (4)	26,750	19,335		26,464	18,552		53,214	37,887
Total operating expenses	128,789	109,824		135,904	111,055		264,693	220,879
Operating income (loss)	(6,081)	13,962		391	26,232		(5,690)	40,194
Interest income, net	3,287	3,287		2,959	2,959		6,246	6,246
Other income (expense), net	(196)	(196)		77	77		(119)	(119)
Total interest income and other income (expense), net	3,091	3,091		3,036	3,036		6,127	6,127
Income Taxes ⁽⁶⁾	1,797	3,922		3,626	7,024		5,423	10,946
Net income (loss)	\$ (4,787)	\$ 13,131		\$ (199)	\$ 22,244	\$	(4,986)	\$ 35,375
Non-GAAP bridge to GAAP								
(1) Cost of revenue (stock-based compensation)		\$ 780			\$ 764			\$ 1,544
(2) Sales and marketing (stock-based compensation)		6,469			11,047			17,516
(3) Research and development (stock-based compensation)		5,081			5,890			10,971
(4) General and administrative (stock-based compensation)		7,415			7,912			15,327
(5) Intangible asset amortization		298			228			526
(6) Income tax effect of non-GAAP adjustments		(2,125)			(3,398)			(5,523)
Total non-GAAP expenses		\$ 17,918	$\ \ $,	\$ 22,443			\$ 40,361
GAAP net loss		\$ (4,787)			\$ (199)			\$ (4,986)
						_		

Calix's non-GAAP measures are not in accordance with, or an alternative for, GAAP and may be different from non-GAAP measures used by other companies. In addition, the above non-GAAP Consolidated Statements of Income are not based on a comprehensive set of accounting rules or principles.

Calix, Inc. Historical Financial Statements Condensed Consolidated Balance Sheets 2025

ſ\$	in	thousands

Assets		
Current assets:		
Cash and cash equivalents	\$ 42,300	\$ 76,538
Marketable securities	240,010	222,430
Accounts receivable, net	75,511	63,076
Inventory	100,835	110,522
Prepaid expenses and other current assets	103,344	89,748
Total current assets	562,000	562,314
Dranathy and equipment not	20.022	22.445
Property and equipment, net	30,832	32,415
Right-of-use operating leases	5,535	4,736
Deferred tax assets	179,005	178,817
Goodwill	116,175	116,175
Other assets	23,572	26,949
Total assets	\$ 917,119	\$ 921,406
Liabilities and stockholders' equity		
Current liabilities:		
Accounts payable	\$ 23,471	\$ 23,746
Accrued liabilities	69,871	74,122
Deferred revenue	29,482	25,774
Total current liabilities	122,824	123,642
Long-term portion of deferred revenue	21,310	20,111
Operating leases	3,378	2,953
Other long-term liabilities	2,441	2,028
Stockholders' equity:		
Common stock	1,643	1,633
Additional paid-in capital	1,160,781	1,166,266
Accumulated other comprehensive loss	(345)	(115)
Accumulated deficit	(394,913)	(395,112)
Total stockholders' equity	767,166	772,672
• •		. 2,0
Total liabilities and stockholders' equity	\$ 917,119	\$ 921,406

3/29/2025

6/28/2025

Calix, Inc. **Historical Financial Statements Condensed Consolidated Statement of Cash Flows 2025** (\$ in thousands)

Operating	activities

Net loss

Adjustments to reconcile net loss to net cash provided by operating activities:

Stock-based compensation

Depreciation and amortization

Deferred income taxes

Net accretion of available-for-sale securities

Changes in operating assets and liabilities:

Accounts receivable, net

Inventory

Prepaid expenses and other assets

Accounts payable Accrued liabilities

Deferred revenue

Other long-term liabilities

Net cash provided by operating activities

Investing activities:

Purchases of property and equipment

Purchases of marketable securities

Sales of marketable securities

Maturities of marketable securities

Net cash provided by investing activities

Financing activities

Proceeds from common stock issuances related to employee benefit plans

Repurchases of common stock

Net cash used in financing activities

Effect of exchange rate changes on cash and cash equivalents

Net increase (decrease) in cash and cash equivalents

Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period

Qtr Ending 3/29/2025	Qtr Ending 6/28/2025	Ytd Ending 6/28/2025
\$ (4,787)	\$ (199)	\$ (4,986)
19,745	25,612	45,357
4,271	4,342	8,613
(1,459)	174	(1,285)
(1,144)	(993)	(2,137)
3,810	12,435	16,245
1,891	(9,686)	(7,795)
2,808	10,944	13,752
3,486	(1,202)	2,284
(14,086)	3,699	(10,387)
3,158 (481)	(4,906) (839)	(1,748) (1,320)
17,212	39,381	56,593
17,212	39,361	
(4,310)	(2.725)	(0.045)
(36,856)	(3,735) (58,260)	(8,045) (95,116)
(30,830)	11,362	11,362
52,154	65,525	117,679
10,988	14,892	25,880
10,300		
10,845	13,352	24,197
(39,974)	(33,557)	(73,531)
(29,129)	(20,205)	(49,334)
(23,123)	(20,203)	(43,334)
67	170	237
(862)	34,238	33,376
43,162	42,300	43,162
\$ 42,300	\$ 76,538	\$ 76,538